Biocare Medical and Hamamatsu Partner on Integrated Spatial Biology Platform

November 06, 2025
Biocare Medical and Hamamatsu have announced a strategic collaboration to deliver an integrated spatial biology solution combining staining and imaging systems for research institutions and biopharma companies.

Biocare Medical and Hamamatsu have announced a strategic collaboration to offer an integrated spatial biology workflow, according to a press release. The partnership combines Biocare’s ONCORE Pro X automated staining instrument with Hamamatsu’s MoxiePlex multi-spectral imaging system.

The co-exclusive offering provides an end-to-end solution for multiplex immunofluorescence and immunohistochemistry staining through to high-resolution digital imaging. It is designed for use by pharmaceutical and biotech companies, academic research institutions, and contract research organizations.

Hamamatsu’s MoxiePlex system is already being used in research-use-only projects with cancer centers and CROs. The new agreement expands Hamamatsu’s reach in immunohistochemistry and spatial biology by integrating its imaging technology with Biocare’s staining platforms and global distribution network.

The collaboration aims to support more efficient spatial biology and translational research workflows, offering a reproducible and scalable approach for multiplex immunofluorescence applications.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

11/06
Geeks360 Launches AI Platform to Integrate Marketing and Operations for Healthcare Firms
11/06
Fosun Highlights Global Innovation and AI Initiatives at Sustainability Leaders Conference
11/06
Healthcare Triangle Signs LOI to Acquire Teyame.AI for AI-Powered Patient Engagement
11/06
Bain & Company and KLAS Research Report Finds Healthcare AI Focus Shifting to ROI and Workflow Efficiency
11/06
Carta Healthcare Named to CB Insights 2025 Digital Health 50

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like